Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Invest. 2007 Jun;117(6):1456-65.

Gene therapy for severe combined immunodeficiency: are we there yet?

Author information

  • 1INSERM U768 and Université Paris Descartes, Paris, France. m.cavazzana@nck.aphp.fr

Abstract

Inherited and acquired diseases of the hematopoietic system can be cured by allogeneic hematopoietic stem cell transplantation. This treatment strategy is highly successful when an HLA-matched sibling donor is available, but if not, few therapeutic options exist. Gene-modified, autologous bone marrow transplantation can circumvent the severe immunological complications that occur when a related HLA-mismatched donor is used and thus represents an attractive alternative. In this review, we summarize the advantages and limitations associated with the use of gene therapy to cure SCID. Insertional mutagenesis and technological improvements aimed at increasing the safety of this strategy are also discussed.

PMID:
17549248
[PubMed - indexed for MEDLINE]
PMCID:
PMC1878528
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Journal of Clinical Investigation Icon for PubMed Central
    Loading ...
    Write to the Help Desk